Ki67 assessment in breast cancer: an update

Abstract : Although immunohistochemical detection of the Ki67 antigen has been used for many years to assess cancer proliferation, this marker is still not recommended for routine use in clinical management of breast cancer. The major reason for this situation is a lack of a standardised procedure for Ki67 assessment as well as persistence of several issues of debate with regards to the Ki67 assay interpretation and the marker's clinical utility. Nowadays Ki67 assessment is principally used for estimation of prognosis and guiding the decision on adjuvant treatment choice, as well as for prediction of response to neoadjuvant treatment in ER+/HER2- breast cancer. In ER-/HER2+ and ER-/HER2- tumours, high post-neoadjuvant Ki67 index is associated with unfavourable prognosis. We review here the elements impacting analytical validity of the Ki67 immunohistochemical assay, the evidence of its clinical utility and the current recommendations for its use in breast cancer management.
Document type :
Journal articles
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-01675161
Contributor : Frédérique Penault-Llorca <>
Submitted on : Thursday, January 4, 2018 - 10:43:16 AM
Last modification on : Friday, January 5, 2018 - 1:16:27 AM

Identifiers

Collections

Citation

Frédérique Penault-Llorca, Nina Radosevic-Robin. Ki67 assessment in breast cancer: an update. Pathology, Lippincott, Williams & Wilkins, 2017, 49 (2), pp.166 - 171. ⟨10.1016/j.pathol.2016.11.006⟩. ⟨hal-01675161⟩

Share

Metrics

Record views

64